


Alizapride hydrochloride

Cat. No.:	HY-A0125A
CAS No.:	59338-87-3
Molecular Formula:	C ₁₆ H ₂₂ ClN ₅ O ₂
Molecular Weight:	351.83
Target:	Dopamine Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

H₂O : 100 mg/mL (284.23 mM; Need ultrasonic)
DMSO : 33.33 mg/mL (94.73 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM	2.8423 mL	14.2114 mL	28.4228 mL
	5 mM	0.5685 mL	2.8423 mL	5.6846 mL	
	10 mM	0.2842 mL	1.4211 mL	2.8423 mL	

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: PBS
Solubility: 50 mg/mL (142.11 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (7.11 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (7.11 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.11 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Alizapride is a potent antiemetic, acting as a dopamine receptor antagonist. Alizapride also used in human digestive disorders^{[1][3]}.

IC₅₀ & Target

Dopamine receptor^[1]

In Vivo

Alizapride (2.5, 5, 10, 25 μg/kg; SC; 7 consecutive days) significantly reduces the bound IgG-sensitized erythrocytes with

Splenic macrophages isolated from animals^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Duncan–Hartley guinea pigs ^[2]
Dosage:	2.5, 5, 10, 25 µg/kg
Administration:	Alizapride (2.5, 5, 10, 25 µg/kg; SC; 7 consecutive days)
Result:	Reduced the clearance of IgG-sensitized RBCs.

REFERENCES

[1]. Bleiberg H, et al. Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial. *Cancer Chemother Pharmacol.* 1988;22(4):316-20.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA